Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309014181> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4309014181 endingPage "vii107" @default.
- W4309014181 startingPage "vii107" @default.
- W4309014181 abstract "Abstract Diffuse glioma is the most frequent and malignant neuroepithelial tumor in the central nervous system. IDH mutations are the most frequent genetic mutations in adult gliomas. The WHO Classification of Tumors, 5th edition, volume 6: Central Nervous System Tumours revised in 2021, defines the presence of IDH mutations in gliomas as astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted. In addition, more than 90% of IDH mutations found in gliomas are IDH1 R132H mutation. Several clinical trials of mutant IDH1 inhibitors targeting the IDH1 R132H mutation have shown their efficacy, but it has also been reported that IDH1 inhibitors alone may not provide sufficient tumor suppression. In this study, we performed genome-wide knockout screening using CRISPR/Cas9 genome editing technology to search for new drug targets that are synergistic with the mutant IDH1 inhibitor DS-1001b. The results of CRISPR screening and RNA sequence analysis revealed that several metabolism-related genes are factors that define resistance to mutant IDH inhibitor. In a tumor suppression study, treatment of two IDH1 R132H mutant glioma cell lines (MGG152 and BT142) with mutant IDH1 inhibitor suppressed production of the oncometabolite D2-HG, but did not significantly alter cell growth. However, when mutant IDH1 inhibitor were combined with inhibitor for metabolism-related genes, cell survival was significantly reduced, and the effects were synergistic. In this study, we found that administration of mutant IDH inhibitors to IDH mutant gliomas significantly altered intratumor metabolism using various molecular approaches. We then identified targets that, when combined with mutant IDH inhibitor, provide synergistic tumor suppression. These results are expected to provide a new therapeutic approach for a subset of patients who have difficulty responding to mutant IDH1 inhibitors." @default.
- W4309014181 created "2022-11-20" @default.
- W4309014181 creator A5000104222 @default.
- W4309014181 creator A5004935136 @default.
- W4309014181 creator A5018754578 @default.
- W4309014181 creator A5025992534 @default.
- W4309014181 creator A5029897221 @default.
- W4309014181 creator A5029956603 @default.
- W4309014181 creator A5068445312 @default.
- W4309014181 creator A5071918497 @default.
- W4309014181 creator A5088996159 @default.
- W4309014181 date "2022-11-01" @default.
- W4309014181 modified "2023-09-30" @default.
- W4309014181 title "DDDR-39. IDENTIFICATION OF A NOVEL THERAPEUTIC TARGET THAT IS SYNTHETICALLY LETHAL WITH MUTANT IDH INHIBITOR IN GLIOMA USING THE CRISPR/CAS9 GENOME EDITING TECHNOLOGY" @default.
- W4309014181 doi "https://doi.org/10.1093/neuonc/noac209.404" @default.
- W4309014181 hasPublicationYear "2022" @default.
- W4309014181 type Work @default.
- W4309014181 citedByCount "0" @default.
- W4309014181 crossrefType "journal-article" @default.
- W4309014181 hasAuthorship W4309014181A5000104222 @default.
- W4309014181 hasAuthorship W4309014181A5004935136 @default.
- W4309014181 hasAuthorship W4309014181A5018754578 @default.
- W4309014181 hasAuthorship W4309014181A5025992534 @default.
- W4309014181 hasAuthorship W4309014181A5029897221 @default.
- W4309014181 hasAuthorship W4309014181A5029956603 @default.
- W4309014181 hasAuthorship W4309014181A5068445312 @default.
- W4309014181 hasAuthorship W4309014181A5071918497 @default.
- W4309014181 hasAuthorship W4309014181A5088996159 @default.
- W4309014181 hasBestOaLocation W43090141811 @default.
- W4309014181 hasConcept C104317684 @default.
- W4309014181 hasConcept C127848430 @default.
- W4309014181 hasConcept C143065580 @default.
- W4309014181 hasConcept C181199279 @default.
- W4309014181 hasConcept C2777150147 @default.
- W4309014181 hasConcept C2777931997 @default.
- W4309014181 hasConcept C2778227246 @default.
- W4309014181 hasConcept C2778880634 @default.
- W4309014181 hasConcept C501734568 @default.
- W4309014181 hasConcept C502942594 @default.
- W4309014181 hasConcept C54355233 @default.
- W4309014181 hasConcept C55493867 @default.
- W4309014181 hasConcept C86803240 @default.
- W4309014181 hasConcept C98108389 @default.
- W4309014181 hasConceptScore W4309014181C104317684 @default.
- W4309014181 hasConceptScore W4309014181C127848430 @default.
- W4309014181 hasConceptScore W4309014181C143065580 @default.
- W4309014181 hasConceptScore W4309014181C181199279 @default.
- W4309014181 hasConceptScore W4309014181C2777150147 @default.
- W4309014181 hasConceptScore W4309014181C2777931997 @default.
- W4309014181 hasConceptScore W4309014181C2778227246 @default.
- W4309014181 hasConceptScore W4309014181C2778880634 @default.
- W4309014181 hasConceptScore W4309014181C501734568 @default.
- W4309014181 hasConceptScore W4309014181C502942594 @default.
- W4309014181 hasConceptScore W4309014181C54355233 @default.
- W4309014181 hasConceptScore W4309014181C55493867 @default.
- W4309014181 hasConceptScore W4309014181C86803240 @default.
- W4309014181 hasConceptScore W4309014181C98108389 @default.
- W4309014181 hasIssue "Supplement_7" @default.
- W4309014181 hasLocation W43090141811 @default.
- W4309014181 hasOpenAccess W4309014181 @default.
- W4309014181 hasPrimaryLocation W43090141811 @default.
- W4309014181 hasRelatedWork W2060806939 @default.
- W4309014181 hasRelatedWork W2081712124 @default.
- W4309014181 hasRelatedWork W2117996853 @default.
- W4309014181 hasRelatedWork W2137361994 @default.
- W4309014181 hasRelatedWork W2414858932 @default.
- W4309014181 hasRelatedWork W2740327985 @default.
- W4309014181 hasRelatedWork W2767753965 @default.
- W4309014181 hasRelatedWork W2967546255 @default.
- W4309014181 hasRelatedWork W3048033855 @default.
- W4309014181 hasRelatedWork W4200111615 @default.
- W4309014181 hasVolume "24" @default.
- W4309014181 isParatext "false" @default.
- W4309014181 isRetracted "false" @default.
- W4309014181 workType "article" @default.